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Factors that sustain self-renewal of mouse embry-
onic stemcells (ESCs) arewell described. In contrast,
the machinery regulating exit from pluripotency is ill
defined. In a large-scale small interfering RNA
(siRNA) screen, we found that knockdown of the
tumor suppressors Folliculin (Flcn) and Tsc2 prevent
ESC commitment. Tsc2 lies upstream of mammalian
target of rapamycin (mTOR), whereas Flcn acts
downstream and in parallel. Flcn with its interaction
partners Fnip1 and Fnip2 drives differentiation by re-
stricting nuclear localization and activity of the bHLH
transcription factor Tfe3. Conversely, enforced
nuclear Tfe3 enables ESCs to withstand differentia-
tion conditions. Genome-wide location and func-
tional analyses showed that Tfe3 directly integrates
into the pluripotency circuitry through transcriptional
regulation of Esrrb. These findings identify a cell-
intrinsic rheostat for destabilizing ground-state plu-
ripotency to allow lineage commitment. Congruently,
stage-specific subcellular relocalization of Tfe3 sug-
gests that Flcn-Fnip1/2 contributes to develop-
mental progression of the pluripotent epiblast in vivo.INTRODUCTION
Stem cell fate is determined by a balance between pro-self-
renewal and pro-differentiation signals. To initiate differentiation,
stem cells have to be forced out of self-renewal, the trans-
criptional networks conferring stem cell identity need to be
dissolved, and lineages have to be chosen. How these interde-
pendent tasks are coordinated is poorly understood. Mouse
embryonic stem cells (ESCs) provide a tractable system for dis-
secting this process because intrinsic and extrinsic signals regu-
lating self-renewal are reasonably well defined.
Genetic and biochemical studies have shown that activity of
mitogen-activated protein kinase (MAPK) (Kunath et al., 2007)and glycogen synthetase kinase-3 (GSK3) (Doble et al., 2007)
prime ESCs for differentiation. Chemical inhibition of both (2i)
promotes robust self-renewal (Ying et al., 2008). It is therefore
hypothesized that shielding ESCs from differentiation cues is
sufficient for stabilization and propagation of a naive pluripotent
ground state (Nichols and Smith, 2009).
Pluripotency is governed by a transcription factor network
that contains numerous autoregulatory loops, suggestive of
self-propagation (Jaenisch and Young, 2008). How this recur-
sive circuitry is extinguished in an orderly manner to enable
developmental progression and eventual lineage commitment
is currently unclear. Endogenous repressors Tcf3 (encoded
by Tcf7l1) and the NuRD complex (Kaji et al., 2006; Nichols
and Smith, 2012; Pereira et al., 2006) play a role, but other
key drivers of exit from naive pluripotency have yet to be
identified.
Delineation of mechanisms that steer ESCs into differentiation
may reveal predetermined breaking points in the pluripotent
transcription factor network. Furthermore, factors regulating
ESC fate transition are candidates to drive progression of the
naive preimplantation into the lineage-poised postimplantation
epiblast in vivo (Nichols and Smith, 2009).
Here, we exploited the ground-state culture system to screen
functionally for genes promoting exit from naive pluripotency.RESULTS
A Large-Scale siRNA Screen Identifies Genes Required
for Exit from Ground-State Pluripotency
To uncover genes that are required for progression from naive
pluripotency into a state primed for differentiation, we used a
simple monolayer differentiation protocol (Ying et al., 2003). Effi-
cient loss of ESC identity over 3 days (Figures 1A and 1B) is a
time window compatible with perdurance of transient knock-
down by siRNA. We assayed for resistance to exit the ESC state
by ability to proliferate in selective 2i culture conditions plus re-
tained expression of the Oct4 locus. After transfecting siRNAs
in 2i, differentiation was enabled by withdrawal of the inhibitors.
Resistance to commitment was then assayed by reapplying
inhibitors and selecting for Oct4 expression (Figure 1A). AfterCell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc. 335
Figure 1. A Large-Scale siRNA Screen for Genes Regulating ESC Commitment
(A) Outline of the screening procedure; O4GIP ESCs were transfected with siRNAs in 2i, differentiation enabled by inhibitor removal, and resistance to
commitment assayed by restoring 2i with puromycin selection for Oct4 expression.
(B) Exit from pluripotency in differentiating O4GIP ESCs transfected with indicated siRNAs assayed after 24 hr, 48 hr, and 72 hr and stained for AP.
(C) Average screen Z scores. Red and green triangles show validated hits (see Figure S1B); gray triangles show duplicates within the transcription factor subset.
(D) O4GIP ESC resistance to commitment after transfection with siRNAs was quantified with a cell viability assay and normalized to no siRNA transfection
controls. Pools and individual siRNAs are shown. Note that Tsc1 was not recovered in the primary screen. For siRNA pools, the average and standard deviation
(SD) of two technical replicates is shown.
See also Figure S1.72 hr, cells transfected withGFP, Klf4, orNr0b1 siRNAs lost ESC
properties, but upon knockdown of FGF4,GSK3a/b, or Tcf3, sig-
nificant numbers of alkaline phosphatase (AP) expressing ESCs
were recovered (Figure 1B).
To allow quantitation at high throughput, commitment resis-
tance was measured by cell survival. We screened roughly
9,900 genes in duplicate experiments with pools of four indepen-
dent siRNAs. Z scores were determined for each run (Figure 1C
and Figure S1A available online). Seventy genes that stringently
scored positive (Z > 3 and Z > 2.5 in the two trials) were inter-
sected with RNA-sequencing data from ESC differentiations
(T. Kalkan and A.S., unpublished data), and 17 genes were
excluded due to lack of expression. Another 7 genes were
manually eliminated as likely false-positives (see Extended
Experimental Procedures). The remaining 46 primary hits were
retested, and 28 validated with at least two different siRNAs (Fig-
ure S1B). These include Tcf3 and other members of the path-
ways inhibited in 2i culture conditions (Figure 1D), indicating
that the screen successfully identified genes regulating exit
from ESC pluripotency.336 Cell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc.Folliculin Regulates Exit from Pluripotency
We focused on the tumor suppressor Folliculin (Flcn) (Nickerson
et al., 2002) because a role in pluripotency has not been
described, but homozygous knockout alleles show early embry-
onic lethality (Chen et al., 2008a; Hasumi et al., 2009).
Rex1GFPd2 ESCs that quantitatively report differentiation
(Marks et al., 2012; Wray et al., 2011; Yang et al., 2012) were
engineered to express a small hairpin RNA (shRNA) targeting
Flcn, resulting in reduced transcript and protein (Figures S2A
and S2B). Twenty-four hours after 2i withdrawal, control cells
downregulated GFP, whereas Flcn shRNA knockdown lines
maintained expression (Figure 2A). This phenotype could be
partially reverted by a Flcn transgene designed to be shRNA
resistant (Figure S2C). Maintenance of GFP expression at 24 hr
without 2i was also observed after transient knockdown with
siRNA transfection (Figures S2D and S2G). Replating differenti-
ating control cells after 3 days into 2i conditions with Rex1-
expression selection gave very few AP-positive colonies,
whereas Flcn knockdown cells yielded many (Figure 2B). We
used colony-forming assays to quantify 10%–15% of cells in
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Figure 2. Flcn Regulates ESC Commitment
(A) Flow cytometry profile of Rex1GFPd2 expression in Flcn shRNA knockdown clones (Flcn.2,4) and controls (ctrl.1,2) in 2i conditions (left panel) and after 24 hr of
2i withdrawal (right panel).
(B) Flcn shRNA cell lines and controls kept in 2i (10-fold fewer cells) or differentiated for 72 hr in N2B27, or N2B27 supplemented with 10% FBS or 25 ng/ml FGF4,
10 ng/ml BMP4, and 20 ng/ml Activin A, were replated in 2i and selected in blasticidin for Rex1 expression. Resulting ESC colonies were visualized by AP staining.
(C and D) Differentiating Flcn shRNA cell lines (C) or Flcn shRNA cell lines expressing an empty vector or shRNA-resistant Flcn transgene (rescue) (D) and
respective controls were replated at clonal density, and colonies arising from uncommitted cells stained for AP. Average clonogenicity and SD are relative to
number of plated cells of two independent experiments.
(E) CreERT2-expressing clones of indicated genotypes were treated with Tam, differentiated for 3 days, and uncommitted cells quantified in 2i/LIF. Average and
SD are of at least three independent biological replicates.
See also Figure S2.Flcn shRNA knockdown cell lines as uncommitted 3 days after
inhibitor withdrawal (Figure 2C). This is a conservative estimate
because cloning efficiency of ESCs is typically only 50% (Wray
et al., 2010). The phenotype could be rescued with the transgene
(Figures 2D and S2E). Resistance to differentiation was also
observed in the presence of Activin A, fibroblast growth factor
4 (FGF4), and bonemorphogenetic protein 4 (BMP4) or 10% fetal
bovine serum (Figure 2B), suggesting that Flcn is important for
exit from pluripotency under different inductive regimes.
To confirm these findings in a genetic null background, we
derived ESCs from Flcnflox/+ intercrosses (Hasumi et al., 2009).
Cells were stably transfected with a plasmid expressing Cre
fused to the ligand-binding domain of the estrogen receptor
(ERT2), and single-cell clones expanded. After treatment with
4-Hydroxytamoxifen (Tam) to activate Cre, Flcn protein was
undetectable in two independently derived knockout ESC lines
(Figure S2F). After 3 days of differentiation, wild-type and hetero-
zygous cells lost colony-forming ability, whereas 20%–30% of
the knockout cells generated undifferentiated colonies (Fig-
ure 2E). These observations confirm that Flcn expedites exit
from the ESC state.Folliculin Acts downstream of, or in Parallel to, mTOR
and Together with Fnip1/2
Flcn has been linked to mammalian target of rapamycin (mTOR)
kinase signaling (Baba et al., 2006; Hartman et al., 2009; Piao
et al., 2009). The mTOR inhibitor Tsc2 scored as a commitment
regulator in our screen (Figure 1D). Tsc2 functions as a hetero-
dimer with Tsc1 (Laplante and Sabatini, 2012), and knockdown
of Tsc1 also inhibited exit from pluripotency (Figure 1D). How-
ever, we found that mTOR was strongly activated after inhibitor
withdrawal, leading to increased phosphorylation of ribosomal
protein S6 (S6), S6kinase, and the translational regulator
4EBP1 (Figure 3A). The phosphorylation kinetics differed; in
particular, S6 and 4EBP1 phosphorylation peaked at 24 hr and
48 hr, respectively. These effects are not due to starvation in
N2B27 as they were also observed in serum. To test whether
activation of mTOR is important for ground-state exit, we quan-
tified undifferentiated ESCs at 24 hr, 36 hr, and 48 hr of 2i
withdrawal in the presence or absence of the mTOR inhibitor
rapamycin (Rapa) (Figure 3B). No difference was detected. As
expected, knockdown of Tsc2 increased S6 phosphoryla-
tion (Figure S3A) and impaired Rex1GFPd2 downregulationCell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc. 337
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Figure 3. FlcnActs downstreamof or in Par-
allel to mTOR and Interacts with Fnip1/2
(A) Rex1GFPd2 cells were differentiated in N2B27
with and without 20 nM Rapa (left panel) or in
N2B27/10%FBS (right panel), and cell lysates
probed with indicated antibodies.
(B) Rex1GFPd2 cells differentiated in N2B27 with
and without 20 nM Rapa were replated at single-
cell density in 2i including Rex1-expression
selection at the indicated time points. The average
percentage of uncommitted cells forming AP-
positive colonies relative to the number of cells
plated and SD are of two technical replicates.
(C) Rex1GFPd2 cells transfected with indicated
siRNAs were differentiated for 72 hr in N2B27 with
and without 20 nM Rapa and replated in 2i with
Rex1-expression selection, and resulting colonies
were stained for AP.
(D) Proteins were immunoprecipitated with FLAG
antibodies from stably transfected Rex1GFPd2
cells cultured in 2i or differentiated for 40 hr and
probed with indicated antibodies.
(E) mRNA levels were quantified during differenti-
ation and normalized to 2i-cultured cells. Average
and SD are of two cell lines.
(F) O4GIP ESCs were transfected with indicated
siRNAs, and after differentiation for 3 days, exit
from pluripotency quantified with a cell-viability
assay and normalized to no siRNA transfection
controls. Average and SD are of two technical
replicates.
See also Figure S3.(Figure S2D). Blocking mTOR with Rapa in this context abro-
gated the differentiation defects (Figure 3C). These data indicate
that elevated activity of mTOR in ESCs impedes exit from self-
renewal, but that activation during differentiation is not required
for cell-fate transition. Rapa did not affect Tcf3 or Flcn knock-
down phenotypes (Figure 3C), suggesting that Flcn acts down-
stream or independent of mTOR.
Flcn has been reported to bind to two Flcn-interacting pro-
teins, Fnip1 and Fnip2 (Baba et al., 2006; Hasumi et al., 2008;
Takagi et al., 2008). To identify binding partners in ESCs,
we immunopurified (IP) Flcn from cells expressing functional
33FLAG-Flcn (data not shown). Silver staining revealed the
presence of one specific copurifying protein at approximately
130 kDa that was identified as Fnip1 bymass-spectrometry (Fig-
ure S3B, arrowhead). Vice versa, 33FLAG-Fnip1 copurified one
specific protein with a molecular weight similar to that of Flcn
(Figure S3B, open arrowhead). Endogenous Fnip1 and Flcn
were detected in 33FLAG-Flcn and 33FLAG-Fnip1 IPs, respec-
tively (Figure 3D), confirming the presence of a Flcn-Fnip1 pro-
tein complex in ESCs.
Flcn, Tsc1, Tsc2, and Fnip1 messenger RNA (mRNA) levels
did not change markedly during early differentiation as
compared to downregulation of Nanog and upregulation of
FGF5 (Figure 3E). Furthermore, Flcn or Fnip1 overexpression
did not induce transcriptional changes indicative of differentia-
tion (Figure S3C) or accelerate ESC commitment (Figure S3D).338 Cell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc.This suggests that Flcn and Fnip1 levels are not limiting for exit
from pluripotency.
To test the functional significance of the Flcn-Fnip1 interac-
tion, we knocked down Fnip1 and its homolog Fnip2 and
assayed loss of ESC identity after 2i withdrawal. Although neither
Fnip1 nor Fnip2 single knockdown had a strong impact, knock-
down of both had a comparable effect to loss of Flcn (Figures 3F
and S3E). Consistent with this, Rex1GFPd2 cells transfected
with Fnip1/2 siRNAs retained GFP expression after 24 hr of with-
drawal from 2i (Figure S2D).
To investigate whether the functions of mTOR and Flcn in
regulation of pluripotency are ESC specific, we turned to postim-
plantation epiblast stem cells (EpiSCs) (Brons et al., 2007; Tesar
et al., 2007). EpiSCs expressOct4, Flcn, Fnip1/2, Tcf3, and Tsc1/
2 (Hayashi et al., 2011). O4GIP EpiSCs were induced to differen-
tiate for 3 days through withdrawal of growth factors and
assayed for commitment by reapplying EpiSC culture conditions
and selecting for Oct4 expression. Neither Tcf3, Tsc2, Flcn, nor
Fnip1/2 knockdown impaired EpiSC differentiation (Figure S3F),
suggesting that the role of these factors is specific to the cell
context.
Flcn Regulates Tfe3 Localization and Activity
Flcn regulates nuclear translocation of the bHLH transcrip-
tion factor Tfe3 in human kidney cells and mouse embryonic
fibroblasts (Hong et al., 2010). Tfe3 showed heterogeneous
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Figure 4. Flcn Regulates Subcellular Localization of Tfe3
(A) Control (ctrl.1), Flcn shRNA (Flcn.4), and Tfe3 shRNA (Tfe3.3) cell lines were stained for Tfe3 and DNA in 2i conditions (left panel) and 24 hr after inhibitor
withdrawal (right panel). Tfe3 was detected in the nucleus (arrowhead) and cytoplasm (open arrowhead).
(B) Cytoplasmic (C) and nuclear (N) fractions of control and Flcn shRNA cells probed with indicated antibodies (open arrowheads indicate Fnip1 and Flcn bands;
both bands recognized by Tfe3 antibodies are specific and likely represent phosphorylation variants; Hong et al., 2010).
(C) Box and whisker plots of nuclear/cytoplasmic Tfe3 ratios in ESCs transfected with indicated siRNAs in 2i conditions and 24 hr after inhibitor withdrawal.
Indicated cell numbers (white) from three experiments with two ESC lines were quantified. (**) and (*) indicate Student’s t test values < 13 10100 and 13 1050,
respectively.
(D–F) Tfe3 is localized to the nucleus (arrowhead) at E3.5 (D). At E4.5, Tfe3 is found in the nucleus and cytoplasm of Nanog-positive epiblast cells (arrowhead) but
stays nuclear in GATA4-positive (open arrowhead) primitive endodermal cells (E). At E5.5, Tfe3 is enriched in the cytoplasm (arrowhead) of Oct4-positive epiblast
cells and remains nuclear (open arrowhead) in extraembryonic endoderm cells (F).
See also Figure S4.subcellular localization in ESCs in 2i and could be detected in the
nucleus (Figure 4A, left panel, arrowhead), cytoplasm (Figure 4A,
left panel, open arrowhead), or both compartments. Stainingwas specific as it was reduced in Tfe3 shRNA knockdown cells
(Figure 4A, lower panel). Tfe3 mRNA levels did not change
distinctly during ESC differentiation (Figure 3E), but we observedCell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc. 339
a marked cytoplasmic relocalization (Figure 4A, right panel). In
contrast, most Flcn shRNA cells featured exclusively nuclear
Tfe3 in 2i (Figure 4A, left panel), and many retained nuclear pro-
tein after inhibitor withdrawal (Figure 4A, right panel, arrowhead).
Consistently, biochemical nucleocytoplasmic fractionations
showed more Tfe3 in the nuclear fraction of Flcn shRNA knock-
down cells compared to control ESCs (Figure 4B). Tfe3 was also
enriched in the nuclei of Flcn null ESCs (Figure S4A). We used
automated image quantification to determine nuclear-cyto-
plasmic ratios of Tfe3 in siRNA-treated cells (see Extended
Experimental Procedures). Compared to controls, knockdown
of Flcn and Fnip1/2 lead to a significant increase in nuclear
Tfe3 both in 2i conditions and 24 hr after inhibitor withdrawal
(Figure 4C). Importantly, this was not an indirect consequence
of maintained ESC identity, as Tcf3-depleted cells showed cyto-
plasmic Tfe3. Knockdown of Tsc2 increased nuclear Tfe3 con-
centration in an mTOR-dependent manner (Figures 4C and
S4B), although less pronounced than after knockdown of Flcn
or Fnip1/2. These observations suggest that Flcn-Fnip1/2 and
Tsc2 activities converge on subcellular localization of Tfe3 and
that nuclear exclusion of Tfe3 normally correlates with loss of
ground-state pluripotency.
In EpiSCs, Tfe3 is exclusively cytoplasmic (Figure S4C). We
therefore examined Tfe3 localization in the embryo. Tfe3 was
localized in the nuclei of both inner cell mass (ICM) (Figure 4D,
arrowhead) and trophectoderm (TE) cells at embryonic day (E)
3.5. At E4.5, Tfe3 could be detected in nuclei and cytoplasm of
Nanog-positive epiblast cells (Figure 4E, arrowhead) but was
exclusively nuclear in GATA4-positive hypoblast (Figure 4E,
open arrowhead) and TE cells. In postimplantation E5.5
embryos, Tfe3 was strongly expressed but excluded from the
nucleus in Oct4-positive epiblast cells (Figure 4F, arrowhead),
whereas it remained nuclear in the extraembryonic endoderm
(Figure 4F, open arrowhead). Thus, nuclear exclusion of Tfe3 in
the epiblast correlates with progression from the naive preim-
plantation state to the postimplantation egg cylinder.
Tfe3 Acts in ESC Commitment
To test whether Tfe3 is functionally downstream of Flcn-Fnip1/2,
we performed simultaneous siRNA transfections. Knockdown of
the pluripotency-associated genes Klf4, Rex1, or Stat3 did not
restore commitment in Tcf3-, Flcn-, Fnip1/2-, or Tsc2-depleted
cells. However, knockdown of Tfe3 completely suppressed the
Flcn, Fnip1/2, and Tsc2 phenotypes although only mildly
affecting Tcf3-dependent commitment (Figures 5A and S5A).
Conversely, transfection of Flcn or Fnip1/2 siRNAs had little
impact in Tfe3 shRNA knockdown cells (Figure S5B). Thus,
Tfe3 is epistatic to Flcn, Fnip1/2, and Tsc2.
Upon depletion of Tfe3, we saw no effect on self-renewal in 2i
but a reduction in ESC clonogenicity 24 hr after inhibitor with-
drawal (Figures 5B and S5C). Interestingly, knockdown of the
Tfe3 familymember Tfeb had little effect on its own.We conclude
that Tfe3 is not essential for naive pluripotency but constrains
exit from ESC self-renewal.
To examine whether nuclear Tfe3 is sufficient to prevent loss
of pluripotency, we generated ESCs expressing Tfe3 fused to
ERT2 to allow for induction of nuclear translocation by Tam.
Tfe3 and Tfe3-ERT2 transfectants were withdrawn from 2i in340 Cell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc.the absence or presence of Tam and, after 3–4 days, replated
in 2i with selection for Rex1 expression. Whereas Tfe3-express-
ing cells exhibited only mild commitment defects, Tam-induced
Tfe3-ERT2-expressing cells showed significantly reduced exit
from the ESC state (Figures 5C and 5D). To address the timing
of Tfe3 action, we pulsed exposure to Tam. Induction during the
first 24 hr after 2i withdrawal was sufficient to impair commit-
ment, whereas later Tam treatment gave weaker phenotypes
(Figure 5E). Rex1GFPd2 cells expressing Tfe3-ERT2 maintained
GFP after 24 hr in N2B27 in the presence of Tam (data not
shown). Even after 76 hr, Rex1GFPd2 expression was main-
tained in a substantial subset of cells (10%–20%) (data not
shown). To test whether this heterogeneous response is due
to Tfe3-ERT2 expression variation within the pool of transfec-
tants or due to variable phenotypic penetrance, we picked
clones with defined expression levels. Indeed, higher expres-
sion and, consequently, more nuclear Tfe3 (Figure S5D) corre-
lated with a higher frequency of GFP maintenance after 3 days
of differentiation (Figure S5E). These data are consistent with
nuclear Tfe3 inhibiting initial events in the exit from naive
pluripotency.
To test for possible crosstalk between the Flcn-Fnip1/2-Tfe3
axis and the differentiation-promoting activities of GSK3 or
MAPK signaling, we analyzed downstream targets. FGF4
induces Etv4 and Spry4 (Lanner et al., 2010), whereas GSK3
inhibition derepresses Axin2 and Cdx1 (Martello et al., 2012;
Wray et al., 2011). Upon removal of the respective inhibitor,
mRNA levels changed similarly to those in controls in Flcn
shRNA, Flcn knockout, or ectopic nuclear Tfe3 cell lines (Fig-
ure S5F and data not shown). Thus, Tfe3 is unlikely to generally
inhibit GSK3 or MAPK signaling. Overlap between pathways
regulating ESC self-renewal is well documented (Martello et al.,
2012; Nichols and Smith, 2012; Niwa et al., 2009; Wray et al.,
2010), and we therefore tested whether Flcn and Tfe3 could
compensate for GSK3 or MAPK inhibition. Flcn shRNA or
ectopic nuclear Tfe3 ESC lines cultured in the presence of either
inhibitor alone maintained higher Rex1GFPd2 expression
compared to the respective controls even after serial passaging
(Figure S5G). This indicates that Flcn-Fnip1/2-Tfe3 operates
independently of GSK3 or MAPK signaling as a third module to
enable ESC differentiation.
ESC differentiation products can be converted into EpiSCs by
continuous exposure to FGF2 and Activin A (Guo et al., 2009).
After three passages in these culture conditions, both Tfe3-
ERT2-expressing and Flcn knockdown cell populations acquired
a transcriptional signature similar to that of EpiSCs (Figure S5H,
upper panel). However, a small percentage of cells remained
clonogenic in 2i (Figure S5H, lower panel), suggesting that
nuclear Tfe3 reduces transition into a postimplantation cell fate
even in a prolonged and highly inductive context.
Ablation of signals mediating exit from the ESC state during
differentiation might also facilitate reprogramming. However,
neither depletion of Flcn, Fnip1/2, or Tsc2 nor nuclear transloca-
tion of Tfe3 enhanced reprogramming of O4GIP EpiSCs into
naive pluripotent ESCs, even in sensitized backgrounds overex-
pressing Klf4 (Guo et al., 2009) and Nanog (Silva et al., 2009), or
hyperactive LIF-STAT3 signaling (Yang et al., 2010) (Figures S5I
and S5J and data not shown). Thus, Flcn-Fnip1/2-Tfe3 acts
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Figure 5. Tfe3 Is Required and Sufficient to Impair ESC Commitment
(A) Commitment of O4GIP cells transfected with the indicated siRNA combinations assayed after 72 hr of differentiation by reapplying 2i culture conditions and
Oct4-expression selection. Exit from pluripotency was quantified with a cell-viability assay and normalized to negative siRNA treatment. Average and SD are of
two technical replicates.
(B) Rex1GFPd2 cells were transfected with indicated siRNAs and exposed for 24 hr to the indicated culture conditions, and ESCs were quantified by replating
single cells in 2i with Rex1-expression selection. Average clonogenicity relative to negative siRNA and SD are of four independent experiments.
(C and D) Rex1GFPd2 cells expressing indicated constructs were differentiated in the absence or presence of 0.1 mMTam for 100 hr and replated in 2i with Rex1
selection (five times fewer cells were replated for cells kept in 2i), and resulting ESC colonies were visualized with AP (C). Cells differentiated for 72 hr were
replated at clonal density, and resulting colonies arising from uncommitted cells stained for AP (D). Average clonogenicity relative to number of plated cells and
SD are of two independent experiments.
(E) O4GIP ESCs expressing an empty vector or Tfe3-ERT2 were differentiated in the indicated intervals with 0.1 mM Tam and EtOH and switched back to 2i with
puromycin selection, and ESCs were quantified with a cell-viability assay. Average fold changes over empty vector control at 72 hr EtOH and SD are from two
technical replicates.
See also Figure S5.specifically in exit from pluripotency during differentiation and
not in acquisition of pluripotency during reprogramming.
Identification of Tfe3 Downstream Targets
To explore the molecular function of Tfe3 downstream of Flcn,
we performed chromatin immunoprecipitation coupled to deep
sequencing (ChIP-Seq). We identified 6,789 peaks in control
and 8,941 peaks in Flcn shRNA cell lines. Cluster analysis
showed a high overlap between both Tfe3 ChIP data sets (Fig-
ures S6A and S6B), and de novo motif recognition identified a
modified E box in more than 80% of bound loci in both experi-
ments (Figure S6C). This suggests that Flcn-Fnip1/2 regulates
the amount of chromatin-bound Tfe3 rather than binding speci-
ficity. Consistent with this, normalized read numbers per peak
region were greater in Flcn shRNA compared to control cells
(Figure S6D).
We compared Tfe3 binding with published ESCChIP data sets
(Martello et al., 2012). Cluster analysis of peak regions (Fig-
ure S6A) and associated genes (Figure S6B) showed that theTfe3-binding profile is distinct and well separated from that of
a group containing the bHLH transcription factor n-Myc but
closer to the core pluripotency factor family including Oct4,
Nanog, and Sox2. The majority of sites occupied by Oct4,
Sox2, Nanog, and Tcf3 are distant from sites bound by Tfe3 (Fig-
ure S6E). However, a significant fraction of common target genes
of Oct4, Sox2, Nanog, and Tcf3 are associated with Tfe3 sites
(Figure S6F). This group is more likely transcriptionally up- or
downregulated during ESC differentiation compared with genes
exclusively bound by Tfe3 (Figure S6G), suggesting a functional
relationship between Tfe3 and the pluripotency network.
Because pluripotency transcription factors are strongly
relayed onto themselves and exhibit pronounced colocation
(Chen et al., 2008b), we examined the overlap of Tfe3, Oct4,
Sox2, Nanog, and Tcf3 peaks (Table S1). Co-occupied loci
included putative cis-regulatory elements in the pivotal pluripo-
tency regulators Klf2, Esrrb (Figure 6A), and Tbx3 (data not
shown), suggesting that these may be nodes where Tfe3 con-
nects to the pluripotent circuitry.Cell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc. 341
Figure 6. Genome-wide Tfe3-Target Determination Identifies Esrrb as a Downstream Effector of Flcn-Fnip1/2-Tfe3
(A) Gene tracks of loci identified by Tfe3 ChIP-Seq with control (ctrl.2), Flcn shRNA (Flcn.4), and Tfe3 shRNA (Tfe3.3) cell lines, overlaid with Nanog-, Oct4- and
Tcf3-bound regions.
(B) ESCs expressing indicated constructs were treated for 3 hr with 0.1 mMTam in 2i. AveragemRNA fold changes relative to EtOH treatment and SD are from two
independent experiments with three different cell lines per genotype. (*) indicates Student’s t test values < 0.005.
(C) Average mRNA changes in ESCs transfected with the indicated siRNA combinations. Average relative expression normalized to no and negative siRNA
treatments and SD are of three independent experiments. (*) indicates Student’s t test values < 0.05.
(D) O4GIP ESCs expressing Tfe3-ERT2 were transfected with indicated siRNAs, differentiated for 3 days in the presence of 0.1 mM Tam or EtOH, and switched
back to 2i with puromycin selection, and remaining ESC colonies were quantified with a cell-viability assay. Average fold changes over negative siRNA-trans-
fected, EtOH-treated cells and SD are from two independent experiments. (**) and (*) indicate Student’s t test values < 0.001 and 0.03, respectively.
(E) Commitment of O4GIP cells transfected with indicated siRNA combinations, including two independent Esrrb siRNAs. Exit from pluripotency was quantified
with a cell-viability assay and normalized to negative siRNA treatment. Average and SD are of two technical replicates.
See also Figure S6.To assess functionality of Tfe3 binding, we analyzed mRNA
levels after 3 hr of Tam addition to Tfe3-ERT2-expressing cells.
We included ApoE and Trpm1, which are bound by Tfe3 (data
not shown) and have been described to be regulated by Flcn
(Hong et al., 2010) and the Tfe3 homolog MiTF (Miller et al.,
2004), respectively. In 2i, we detected induction of Trpm1 and
ApoE and a modest but significant upregulation of Esrrb, though
not Tbx3 or Klf2 (Figure 6B). Although only about 2-fold, the342 Cell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc.upregulation of Esrrb is notable on top of the induction by
GSK3 inhibition (Martello et al., 2012). In fact, less than 2-fold
overexpression of Esrrb was sufficient to impede exit from plu-
ripotency (Figures S6H and S6I). To test whether Flcn regulates
this activity of Tfe3, we analyzed target genes after Flcn siRNA
transfection. Indeed, Esrrb, ApoE, and Trpm1 were upregulated
after Flcn knockdown but not after codepletion of Tfe3. In
contrast, an unrelated Tfe3-binding target, Smad7, was not
regulated in ESCs (Figure 6C). These observations suggest that
Flcn may drive exit from pluripotency by restricting nuclear
access of Tfe3 and consequently reducing transcriptional activa-
tion of the core pluripotency factor Esrrb.
To test for functional relevance, we performed epistasis
experiments and knocked down Esrrb, Klf2, Tbx3, and other
pluripotency-associated transcription factors including Nanog
in Tfe3-ERT2-expressing cells. Only knockdown of Esrrb
reduced Tam-dependent resistance to differentiation, by
approximately 50% (Figure 6D). Likewise, cotransfection of
Esrrb siRNAs together with Flcn or Fnip1/2 depletion restored
commitment (Figure 6E). Conversely, nuclear Tfe3 failed to
inhibit exit from the ES cell state in Esrrb knockout cells (Fig-
ure S6J). These results suggest that Esrrb acts epistatically to
Flcn-Fnip1/2-Tfe3. We note, however, that knockdown of Esrrb
alone destabilized self-renewal (Figures 6D and 6E), consistent
with its pivotal role in the pluripotency circuit (Nichols and
Smith, 2012).
Nuclear Tfe3 Maintains an ESC State
Tfe3-ERT2-expressing ESCs differentiated into neural progeni-
tors and neurons in N2B27 (Figure 7A, left panel). In the presence
of Tam, however, many cells resisted differentiation. These
cultures acquired stable morphology within 2–4 passages (Fig-
ure 7A, right panel) and could be propagated in N2B27 contain-
ing Tam for at least 25 passages. Tfe3-ERT2-Tam (TET) cells
derived from Rex1GFPd2 and O4GIP ESCs maintained GFP
expression in approximately 60%–90% and 90% of cells in the
population, respectively (Figure S7A and data not shown). Tran-
script profiling showed that, with the exception of Nanog, TET
cells maintained expression of pluripotency genes at levels
similar to those in 2i cells (Figure 7B) and were distinct from
EpiSCs (Figure S7B). Flcn knockout but not wild-type or hetero-
zygous ESCs could be similarly sustained in N2B27 alone,
although expression levels of pluripotency genes appeared
lower (Figure S7C). The differentiation markers FGF5, GATA3,
and GATA4 were upregulated in both cases (Figures 7B, S7C,
and S7D). To test whether this is because of ongoing differenti-
ation in the cultures, we sorted GFP-high and -low Rex1GFPd2
TET cells. Indeed, GFP-low cells expressed lower levels of plu-
ripotency and higher levels of differentiation markers compared
to GFP-high cells (Figure S7E), indicating that TET cell cultures
show heterogeneity, similar to ESCs in serum/LIF (Marks et al.,
2012).
Withdrawal of Tam caused downregulation of pluripotency
gene expression, whereas the neural progenitor markers Sox1,
Pax6, Hes5, and Ascl1 were induced (Figures 7C and 7D). Both
Flcn knockout cells and TET cells in the presence of Tam self-
renewed at single-cell level, generating AP-positive colonies
with a skirt of negative cells (mixed) but very few AP-negative,
differentiated colonies (Figures 7E and S7F). Addition of a Janus
kinase (JAK) inhibitor did not alter colony composition, indicating
that LIF-JAK signaling is not required for TET cell self-renewal.
Knockdown of Esrrb, but notKlf2,Klf4, or Tbx3, in Rex1GFPd2
TET cells caused downregulation of GFP expression (Fig-
ure S7G), and replating at clonal density showed impaired self-
renewal of Esrrb-depleted cells (Figure 7F). This is further
evidence that Esrrb is specifically required for TET cell self-renewal. In this regard, it is also noteworthy that TET cells self-
renew without GSK3 inhibition.
Plating TET cells in 2i conditions yielded similar numbers of
colonies compared to the presence of Tam, but the majority
were undifferentiated and homogeneously positive for AP (Fig-
ure 7E). This suggests that the TET cell state is fully responsive
to conversion into the naive ground state.
To confirm that TET cells retain embryonic identity and devel-
opmental potential in vivo, cells kept in Tam for six passages
were stably transfected with a GFP-expression plasmid, sorted
for high GFP and after two further passages in Tam injected
into mouse blastocysts. Resulting embryos showed widespread
contribution of GFP-positive cells at E11.5 (Figure 7G). Further-
more, two independently generated TET cell lines contributed
to adult tissues. Extensive coat color chimerism was obtained
with or without pretreatment in 2i in 4/5 or 4/9 and 6/7 or 2/7
mice, respectively (Figures 7H and S7H and data not shown).
DISCUSSION
Exit from the ESC state requires dissolution of the core pluripo-
tency transcription-factor circuit, but how the differentiation
machinery breaks down this network is unclear. Recovery of
several activators in the GSK3 and MAPK pathways (Figure 1D)
indicated that our screen was effective in identifying drivers of
commitment. GSK3, via b-catenin and Tcf3, represses the
orphan nuclear receptor Esrrb, a central member of the pluripo-
tent circuitry (Festuccia et al., 2012; Ivanova et al., 2006; Martello
et al., 2012; Percharde et al., 2012). Besides Tcf3 and the GSK3-
scaffold gene APC, we recovered CtBP2, a Tcf3 interactor that
may act as a transcriptional corepressor (Brannon et al., 1999;
Tarleton and Lemischka, 2010). Autocrine FGF4 signaling drives
ESC differentiation, and we recovered two kinases, KRas and
Raf1, in this pathway as well as the MAPK-scaffold protein
Mapksp1/Mp1 (Westerman et al., 2011). Mp1 is required for
MAPK signaling at late endosomes (Teis et al., 2002), and we
also identifiedHgs/Hrs, an ESCRT-0 complexmember important
for FGF receptor endocytosis and signaling (Chanut-Delalande
et al., 2010).
We found that efficient exit from naive pluripotency requires
components not previously implicated in ESC biology, namely
Flcn-Fnip1/2 and the mTOR regulators Tsc1 and Tsc2, that
converge on relocalization of the bHLH transcription factor
Tfe3. Conversely, enforced nuclear Tfe3 prevents commitment
and maintains an ESC state. Interestingly, Tsc1/2 and Flcn are
tumor suppressors, whereas Tfe3 is a protooncogene. Tfe3-
gene fusions can be causal for renal cell carcinomas, which
also occur in tuberosclerosis due to mutations in Tsc1 or Tsc2
and in Bird-Hogg-Dube´ (BHD) syndrome due to Flcn mutations
(Armah and Parwani, 2010; Linehan et al., 2010). There are differ-
ences in the histopathological classifications of these tumors,
but there may be a common underlying pathway. Consistent
with this, nuclear Tfe3 has been described in BHD kidney can-
cers (Hong et al., 2010).
The Flcn Pathway
The primary sequence of Flcn does not feature recognizable
domains. A Flcn protein complex purified from HEK293 cellsCell 153, 335–347, April 11, 2013 ª2013 Elsevier Inc. 343
Figure 7. Nuclear Tfe3 Maintains an ESC State
(A) Tfe3-ERT2-expressing cells differentiated into neurons (arrowhead) in the absence (left panel) but retained undifferentiated morphology and could be serially
passaged in the presence of 0.1 mM Tam (right panel).
(B) mRNA expression in Rex1GFPd2 and O4GIP TET cells relative to ESCs in 2i conditions. Average and SD are of three independent experiments.
(C) mRNA expression in Rex1GFPd2 TET cells after Tam withdrawal relative to presence of Tam. Average and SD are of two technical replicates.
(D) Immunohistochemistry in Rex1GFPd2 TET cells treated for 6 days with and without 0.1 mM Tam.
(E) TET cells were plated at single-cell density in indicated culture conditions. Resulting colonies were stained for AP (lower panel) and quantified. Average
numbers relative to Tam and SD are from two independent experiments (left bar: Rex1GFPd2, right bar: O4GIP).
(F) Rex1GFPd2 TET cells were transfectedwith indicated siRNAs and replated after 2 days at clonal density in the presence of Tam. Average clonogenicity relative
to negative siRNA and SD are of two independent experiments.
(G) Rex1GFPd2 TET cells stably transfected with a GFP-expressing plasmid were microinjected into blastocysts, and resulting embryos analyzed at E11.5.
Widespread contribution was detected in 4/7 embryos. For comparison, a non-GFP-expressing embryo (arrowhead) of the same litter is shown.
(legend continued on next page)
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contained Fnip1 and AMP kinase (AMPK) (Baba et al., 2006).
Fnip2 has been identified based on sequence homology and
shown to bind to Flcn, Fnip1, and AMPK (Hasumi et al., 2008;
Takagi et al., 2008). Although we only identified Fnip1 in Flcn
IPs, simultaneous knockdown of Fnip1 and Fnip2 was required
for pronounced commitment defects. This may be due to redun-
dancy or a Flcn-independent function of Fnip1/2, but the similar-
ity in phenotypes between Flcn- and Fnip1/2- depleted ESCs is
consistent with them acting in the same pathway. Whereas
absence of Flcn impedes embryogenesis (Hasumi et al., 2009),
Fnip1-deficient mice are viable (Baba et al., 2012; Park et al.,
2012), suggesting redundancy with Fnip2. However, Fnip1 and
conditional Flcn mutants show similar defects in B cell develop-
ment (Baba et al., 2012), indicating that requirement for Fnip2 is
facultative and cell type dependent.
Depletion of Tsc1 or Tsc2, similar to Flcn-Fnip1/2, induced
nuclear accumulation of Tfe3 and impaired exit from pluripo-
tency. Epistasis experiments with rapamycin and Tfe3 are
consistent with mTOR acting upstream of and/or in parallel
with Flcn-Fnip1/2 to inhibit Tfe3-dependent ESC commitment.
Phosphorylation of Flcn downstream of mTOR has been
described (Baba et al., 2006; Piao et al., 2009), suggesting a
linear relationship between Tsc1/2, mTOR, and Flcn-Fnip1/2
(Figure 7I). However, the identity of the kinase and how phos-
phorylation affects Flcn remains to be determined. In vivo,
Tsc1 and Tsc2 knockout mice show defects after gastrulation
at around E10.0 (Kobayashi et al., 1999, 2001), whereas Flcn
mutants are affected by E6.0 (Hasumi et al., 2009). Tsc mutant
embryos feature phenotypic variability and developmental
delay, though, which may suggest earlier defects that are
compensated for by regulative mechanisms.
We postulate that Tsc1/2 and Flcn-Fnip1/2 phenotypes in
ESCs are mediated by nuclear translocation and activation of
Tfe3 (Figure 7I). Depletion of Tfe3 accelerated ESC commitment,
indicating that Tfe3 resists breakdown of the pluripotency
network. However, Tfe3 mutant mice are viable and fertile
(Steingrimsson et al., 2002). MiTF, Tfe3, and Tfeb can interact
with each other (Hemesath et al., 1994), and functional redun-
dancy has been reported (Huan et al., 2006; Steingrimsson
et al., 2002). In fact, although Tfeb was not essential for Tsc2
or Flcn-Fnip1/2 phenotypes (Figures S5A and 6E), its overex-
pression impaired differentiation (data not shown). Thus,
redundancy could explain why Tfe3 mutants have no overt
developmental phenotype. It should also be noted that several
factors important for in vitro ESC self-renewal are dispensable
in the embryo (Nichols and Smith, 2012).
Regulation of Pluripotency
However, early lethality of Flcn mutant embryos is consistent
with a role of the Flcn-Fnip1/2-Tfe3 module in progression of
pluripotency in vivo. We observed a change in subcellular local-
ization of Tfe3, suggesting that Flcn-Fnip1/2 is inactive in the(H) Passage 8 Rex1GFPd2 TET cells were cultured for 2 days in 2i and injected int
visible against black host fur.
(I) Schematic representation of the Flcn-Fnip1/2 pathway and combinatorial input
self-renewal.
See also Figure S7.early ICM and then becomes active in epiblast but not hypoblast
cells. Flcn, Fnip1, Tsc1, and Tsc2 mRNA levels persisted during
ESC differentiation (Figure 3E) and the transition from ICM
to epiblast cell identities (Tang et al., 2010). Furthermore,
Flcn-Fnip1 complex stoichiometry was maintained during exit
from the ESC state (Figure 3D), suggesting posttranscriptional
regulation.
Nuclear exclusion of Tfe3 in postimplantation epiblast cells
appears to coincide with epithelialization prior to gastrulation
and loss of ESC derivation potential (Nichols and Smith, 2011).
Tfe3 similarly translocates into the cytoplasm at the onset of
ESC differentiation and is cytoplasmic in EpiSCs. These obser-
vations suggest that the Flcn-Fnip1/2-Tfe3 module acts as a
cell-fate switch that steers naive early epiblast and ESCs into a
primed postimplantation state in vitro and in vivo.
Flcn-Fnip1/2-Tfe3 activity requires an ESC-specific context,
as nuclear translocation of Tfe3 or knockdown of Tsc2 and
Flcn-Fnip1/2 in EpiSCs did not induce naive pluripotency.
Similarly, ectopic activation of Tfe3 efficiently impeded ESC dif-
ferentiation in the first 24 hr after inhibitor withdrawal, but less so
afterward (Figure 5E).
The ability of nuclear Tfe3 to maintain an ESC state in the
complete absence of pro-self-renewal or antidifferentiation sig-
nals is unprecedented and implies potent input to the transcrip-
tional circuitry sustaining self-renewal (Nichols and Smith,
2012). Functional analysis indicates that transcriptional upregu-
lation of Esrrb is a relevant output of nuclear Tfe3. It is likely that
there are additional Tfe3 targets because TET cells self-renew
without requirement for either MAPK or GSK3 inhibition,
whereas forced expression of Esrrb confers independence
only from the latter (Martello et al., 2012). Nonetheless, it is
striking that transcription of Esrrb is regulated by Flcn-Fnip1/
2-Tfe3, GSK3/b-catenin/Tcf3 (Martello et al., 2012), and Nanog
(Festuccia et al., 2012) (Figure 7I). We surmise that repression
by Tcf3 combined with withdrawal of Tfe3 and downregulation
of Nanog act to ensure prompt and efficient silencing of this
pivotal pluripotency factor at the onset of differentiation. It
remains to be tested whether distinct regulatory inputs act in
parallel or in sequence, but it is striking that absence of Tcf3
does not infringe development prior to gastrulation (Merrill
et al., 2004), suggesting compensatory dependence of Esrrb
on Nanog or Tfe3 in vivo.
In summary, this study has identified a module that was previ-
ously undescribed in ESCs and mediates a switch from naive to
primed pluripotent states. Our findings suggest that nuclear
exclusion of Tfe3 acts as a rheostat for controlled disequilibra-
tion of the regulatory network that establishes ground-state plu-
ripotency in the embryo and sustains ESCs in vitro.EXPERIMENTAL PROCEDURES
Full details are provided in the Extended Experimental Procedures.o C57BL/6 blastocysts. Contribution of the TET cell agouti gene to coat color is
s into Esrrb transcription. (..) denotes additional Tfe3 targets that contribute to
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Mice and Embryos
Chimeras were generated by microinjection into C57BL/6 blastocysts. Animal
experiments were approved by the University of Cambridge Ethical Review
Committee and authorized by the UK Home Office.
Cell Culture
ESCs were maintained in serum-free N2B27 medium containing 2i and, where
indicated, LIF (Wray et al., 2011; Ying et al., 2008). EpiSCs were cultured as
described (Guo et al., 2009).
Commitment Assay
ESCs were plated on gelatin-coated plates at 1.5 3 104 cells/cm2. The next
day, cells were washed with PBS (PAA) and medium changed to N2B27
without 2i or LIF. Commitment of O4GIP ESCs was determined by restoring
2i plus 1 mg/ml puromycin (Sigma). Uncommitted ESCs were quantified after
2–3 days by adding Alamar Blue (Invitrogen), diluted 1:10 in 2i medium, and
read out on a SpectraMax M2 (Molecular Devices). Commitment of other
genotypes was quantified by replating on laminin-coated plates in ESC
medium. For Rex1GFPd2 cells, 10 mg/ml blasticidin (PAA) was added to select
for Rex1 expression.
siRNA Transfection
Cells were reverse transfected with 16.7 nM siRNA in 2i or FGF2/Activin
A containing N2B27 medium with transfection mixes prepared with
RNAiMax or Lipofectamine 2000 (Invitrogen) in OptiMEM (Invitrogen). All
siRNAs with the exception of Tcf7l1/Tcf3 (Dharmacon, L-048614-01-0005)
and Tbx3 (Ambion, 223884 and 223885) were purchased from QIAGEN
(FlexiTube GeneSolution siRNA pools; AllStars Negative Control siRNA,
1027281; GFP-22 siRNA, 1022064). Knockdown of Tcf3 is included as a
reference.ACCESSION NUMBERS
ChIP-Seq data sets have been deposited in the GEO database with the ID
number GSE39815.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2013.03.012.
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